"Asparaginase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
| Descriptor ID |
D001215
|
| MeSH Number(s) |
D08.811.277.087.116
|
| Concept/Terms |
Asparaginase- Asparaginase
- Asparagine Deaminase
- Deaminase, Asparagine
- Colaspase
- Asparaginase II
|
Below are MeSH descriptors whose meaning is more general than "Asparaginase".
Below are MeSH descriptors whose meaning is more specific than "Asparaginase".
This graph shows the total number of publications written about "Asparaginase" by people in this website by year, and whether "Asparaginase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Asparaginase" by people in Profiles.
-
Thamburaj K, Choudhary A. Hyperintense vessel sign: isolated cortical venous thrombosis after L-asparaginase therapy. Pediatr Radiol. 2009 Jul; 39(7):757.
-
Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood. 2000 Sep 01; 96(5):1709-15.
-
Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer. 1992 Jul 01; 70(1):201-6.
-
Powell BL, Kute TE, Craig JB, Lyerly ES, Gregory BW, Do KA, Contento MM, Capizzi RL. Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase. Leukemia. 1990 May; 4(5):316-20.
-
Muss HB, Spell N, Scudiery D, Capizzi RL, Cooper MR, Cruz J, Jackson DV, Richards F, Spurr CL, White DR, et al. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs. 1990 Feb; 8(1):125-30.
-
Capizzi RL, Davis R, Powell B, Cuttner J, Ellison RR, Cooper MR, Dillman R, Major WB, Dupre E, McIntyre OR. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study. J Clin Oncol. 1988 Mar; 6(3):499-508.
-
Capizzi RL, White C. The pharmacologic basis for the efficacy of high-dose Ara-C and sequential asparaginase in adult acute myelogenous leukemia. Yale J Biol Med. 1988 Jan-Feb; 61(1):11-22.
-
Capizzi RL, Powell BL. Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias. Semin Oncol. 1987 Jun; 14(2 Suppl 1):40-50.
-
Powell BL, Capizzi RL, Lyerly ES, Cooper MR. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia. J Clin Oncol. 1986 Jan; 4(1):95-7.
-
Capizzi RL, Powell BL, Cooper MR, Rathmell JP, White JC, Muss HB, Richards F, Jackson DV, Stuart JJ, White DR, et al. Dose-related pharmacologic effects of high dose ara-C and its use in combination with asparaginase for the treatment of patients with acute non-lymphocytic leukemia. Scand J Haematol Suppl. 1986; 44:17-39.